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OBJECTIVE: Technology appraisal systems have been intro-
duced in England, Scotland and Canada in an effort to shorten
the assessment process. The study rationale was to review, sum-
marise and critique appraisals published by each system over the
last two years, in order to draw comparisons and analyse themes
and trends. METHODS: A database was developed to collate
data from submissions appraised by the National Institute for
Health and Clinical Excellence (NICE), the Scottish Medicines
Consortium (SMC) and the Canadian Agency for Drugs and
Technologies in Health (CADTH) between November 1, 2005
and October 31, 2007. Data collated included the total number
of submissions appraised, interventions approved, and time
taken to provide guidance. Inconsistencies in the decisions made
by each appraisals process were also analysed. RESULTS: Over
the two years, a total of 18,135 and 32 submissions were
appraised by NICE, SMC and CADTH, respectively. Of the total
submissions, NICE approved 17; SMC and CADTH approved
75 and 28, respectively. SMC processed 22 re-submissions com-
pared to 1 and 14 by NICE and CADTH, respectively. CADTH
took an average of 6.5 months to provide guidance from the date
of submission compared to 14.2 months taken by NICE. SMC
took the shortest time, providing guidance within an average of
2.4 months. A total of 27 submissions were appraised by more
than one appraisal system, of which 19 resulted in contradictory
types of guidance. CONCLUSION: The number of submissions
appraised and the time taken to receive guidance varies greatly
across the three appraisal systems. NICE have the longest and
perhaps the most rigorous review system reﬂecting the transpar-
ency of guidance issued. In contrast, the SMC issues guidance on
seven times more submissions but reports higher re-submission
rates. Reviewing the system behind appraising technology assess-
ments may inform future strategic and tactical planning of
submissions.
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OBJECTIVE: The UK National Institute for Health and Clinical
Excellence (NICE) issues guidance on the use of new and existing
technologies. Certain new cancer drugs are appraised as part
of the NICE process, either in groups (Multiple Technology
Appraisals) or individually (Single Technology Appraisals). An
analysis in 2006 suggested that cancer drugs had fared quite well
under NICE, with most recommendations being positive.
However, some have argued that negative NICE decisions are
becoming more frequent. METHODS: NICE decisions on cancer
drugs published from May 2000 to January 2008 were analysed.
Recommendations were classed as ‘wholly positive’ (all evalu-
ated drugs / indications recommended for routine NHS use),
‘wholly negative’ (no drug recommended for routine NHS use in
any indication), or ‘mixed’ (positive and negative recommenda-
tions relating to one or more drugs). Separate analyses were
undertaken by appraisal and by drug. RESULTS: To date, 35
appraisals have been published, covering 24 cancer drugs across
11 tumour types. Drugs for breast cancer (38% of drugs evalu-
ated), colorectal cancer (29%) and lung cancer (21%) were most
frequently appraised. The percentage of ‘wholly positive’ pub-
lished cancer appraisals increased from 48% in June 2006 to
51% in January 2008. However, the percentage of drugs with
wholly positive recommendations remained constant at 57%.
The proportion of ‘wholly negative’ appraisals (drugs) rose from
4% (14%) in June 2006 to 14% (19%) by January 2008. The
large increase in ‘negative’ appraisal decisions may be as much to
do with a change in the evaluation process, notably the intro-
duction of Single Technology Appraisals (STAs), as with a pos-
sible change to NICE’s decision criteria. CONCLUSION: The
perception that NICE is reaching more negative decisions on
cancer drugs is supported by the evidence. Further research is
needed to establish whether this observed change adversely
affects patient access to effective therapy.
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PRIORITY SETTING FOR NEWTECHNOLOGIES: POSSIBLE
DETERMINANTS AMONGTHEWORKING POPULATION
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OBJECTIVE: In several countries, decision makers apply eco-
nomic evaluations for decisions about reimbursing new drugs or
technologies. But there seem to be many other factors, besides
cost-effectiveness that play a role in such decisions. The purpose
of this study was to test if a conjoint analysis method can be
applied to elicit the factors that are most decisive to people of
the working population in decisions about reimbursement.
METHODS: A survey was addressed to 150 members of the
working population, whereby virtual new drugs were presented
two by two, according to 5 attributes: 1) drug price; 2)target
population size; 3) patient age; 4) life expectancy after treatment;
and 5) quality of life before and after treatment. Respondents
had to indicate every time if they preferred drug A or drug B to
be reimbursed, whereby drugs differed on several attributes (tra-
ditional conjoint analysis). Respondents also had to spread ten
points over the two drugs (allocation of points technique).
RESULTS: The survey was completed by 122 individuals. The
top three of most inﬂuencing factors in the conjoint analysis were
the age of the patients, the price of the drug and the quality of life
before and after treatment. MRS (marginal rate of substitution)
for Age/Price = 1.067, MRS Age/Quality of life = 1.172, MRS
Age/Life expectancy = 1.434, MRS Age/Population 1.344, MRS
Price/Quality of life = 1.098, MRS Price/Life expectancy
= 1.344, MRS Price/Population size = 1.560, MRS Quality of
life/Life expectancy = 1.223, MRS Quality of life/Population
size = 1.421, MRS Life expectancy/ Population size = 1.162.
The allocation of points technique provided similar results.
CONCLUSION: Both the conjoint analysis method and the allo-
cation of points technique are possible techniques to elicit pref-
erences of the working population. The allocation of points
techniques allows for more ﬁne-tuning of preferences.
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OBJECTIVE: In 1983 the Orphan Drug Act was approved to
provide incentives for development of new drug treatments for
rare diseases. The objectives of this study are to compare the
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characteristics of the orphan drugs (OD) with the non-Orphan
drugs approved by the FDA in the period 1983–2007.
METHODS: All new chemical entities (NCE) approved by the
FDA in the study period were included in the study. Data derived
from the FDA’s Orange Book (OB). Differences between group
means were assessed using the t-test. Differences in proportions
were evaluated using chi-square and Fisher’s exact test.
RESULTS: Between January 4, 1983 and October 3, 2007 the
FDA granted 1749 OD designations and 315 OD approvals for
marketing. NCEs accounted for 17.7% of OD designations and
53.7% of OD approvals. The FDA approved 635 NCEs in the
study period, out of which 17.5% had OD status at the ﬁrst
NDA approval. Sponsors of ODs were more likely (p < 0.001) to
be US companies as compared to non-US companies (64.0% vs.
54.4%) and to have one NCE approval as compared to multiple
NCE during the study period (43.2% vs. 17.6%). ODs were less
likely (p < 0.001) to have at least one patent listed in the OB in
comparison with non-ODs (62.2% vs. 82.8%). ODs had less
patents listed in the OB than non-ODs (mean 1.7 vs. 2.3)
(p < 0.005). Exclusivity period was longer than the patent period
for 41.4% of the ODs and 21.4% of the non-ODs that had
patents listed in the OB (p < 0.001). ODs had less generic com-
petition than non-ODs (18.0% vs. 29.6%) (p < 0.05). CON-
CLUSION: US companies and companies with only one NCE
approval were more likely to use the Orphan drug regulatory
system. Orphan drugs have less number of patents, more exclu-
sivity protection and less generic competition than non-orphan
drugs.
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OBJECTIVE: To compare health care utilization changes
between Medicare beneﬁciaries with two prescription drug
beneﬁt structures who did and did not reach their respective Part
D drug beneﬁt spend threshold in 2006. METHODS: A retro-
spective analysis of a cohort of 28,392 Medicare Advantage
beneﬁciaries continuously enrolled into two distinct drug beneﬁt
structures for the year prior to and after implementation of the
Medicare Part D beneﬁt. The ﬁrst beneﬁt group (Silver) had the
Part D standard drug beneﬁt threshold ($2250) while the second
(Gold) had an enhanced beneﬁt with a higher threshold ($3500).
Poisson, zero-inﬂated Poisson, and negative binomial modeling
were used to compare post-implementation utilization rates with
adjustment for pre-period utilization, demographics and morbid-
ity burden. RESULTS: A total of 1237 (6%) Silver and 526 (8%)
Gold beneﬁciaries reached their threshold. Among both groups,
beneﬁciaries who reached their threshold had greater morbidity
burden and higher rates of pre-period inpatient admissions and
medical ofﬁce and ED visits (all p < 0.001). Among beneﬁciaries
who reached their threshold, there was no change in inpatient
and ED (both p > 0.05) but an increase in medical ofﬁce visit
(p < 0.001) utilization rates in comparable 6-month periods
before and after reaching their threshold. Sub-analyses indicated
that beneﬁciaries with the highest morbidity burden experienced
higher utilization rates (all p < 0.05), but there were no differ-
ences between groups (all p > 0.05). Beneﬁciaries in both groups
who did reach their threshold had higher post-period utilization
rates (all p < 0.001) regardless of age and morbidity burden and
were more likely to die (p < 0.001) compared to beneﬁciaries
who did not reach their threshold. CONCLUSION: Although
many Medicare beneﬁciaries navigate their drug spend threshold
without experiencing increased health care utilization, those with
high morbidity burdens are at risk of increased health care uti-
lization and the potential for adverse outcomes. It is imperative
that strategies be developed that help safeguard vulnerable Medi-
care beneﬁciaries.
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OBJECTIVE: Investigate the variation in Medicare claim-paying
agents (carriers) reimbursement to physicians for chemotherapy
and evaluate the inﬂuence of Medicare carrier chemotherapy
reimbursement on G-CSF choice. G-CSF is an expensive drug to
manage febrile neutropenia with uncertain beneﬁts. METHODS:
Using the national SEER-Medicare linked database, we studied
patients 66 years or older diagnosed as NHL in one of the 13
SEER registry areas from 1994–2002. We grouped counties
within SEER based on Medicare carrier coverage. We then esti-
mated a regression model describing total physician reimburse-
ment during the ﬁrst cycle of chemotherapy (total Medicare part
B and Medicare outpatient reimbursements within 21 days of the
chemotherapy start date) to construct average Medicare chemo-
therapy physician reimbursement measures for these county
groups. Logistic regression was performed to assess the inﬂuence
of Medicare carrier chemotherapy reimbursement on the use of
G-CSF. RESULTS: F test from the regression model showed
statistically signiﬁcant variation in the reimbursement for ﬁrst
cycle chemotherapy by counties grouped by carrier coverage (P
value = 0.0017). We found that Medicare carrier-related chemo-
therapy reimbursement had a non-linear relationship with the
use of G-CSF. Both linear and squared reimbursement terms were
statistically signiﬁcant. An increase in chemotherapy reimburse-
ment from initially low reimbursement levels resulted in a
decrease in the use of G-CSF and this relationship went away at
higher chemotherapy reimbursement levels. CONCLUSION:
Medicare physician reimbursement for chemotherapy varies
across Medicare carriers and this variation affects the decision of
physicians to prescribe G-CSF. At low chemotherapy reimburse-
ment levels, increases in chemotherapy reimbursements decreases
G-CSF prescribing. Physicians appear to compensate for lower
reimbursements by increasing the intensity of their services.
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OBJECTIVE: Little is known about how Medicare Part D utili-
zation varies based on subjects’ pre-Part D prescription coverage
and comorbidities. METHODS: We examined claims from a
national pharmacy chain from 2005 and 2006 accounting for
approximately 15% of the U.S. prescription drug market. We
focused on beneﬁciaries ages 66–79 as of January 1, 2006. We
focused on the association between pre-Part D insurance gener-
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